Karen Basu

615 total citations
12 papers, 444 citations indexed

About

Karen Basu is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Karen Basu has authored 12 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Ophthalmology, 8 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Surgery. Recurrent topics in Karen Basu's work include Retinal Diseases and Treatments (11 papers), Retinal Imaging and Analysis (8 papers) and Retinal and Optic Conditions (5 papers). Karen Basu is often cited by papers focused on Retinal Diseases and Treatments (11 papers), Retinal Imaging and Analysis (8 papers) and Retinal and Optic Conditions (5 papers). Karen Basu collaborates with scholars based in United States, United Kingdom and Australia. Karen Basu's co-authors include Jason S. Ehrlich, David M. Brown, David S. Boyer, Quan Dong Nguyen, Arshad M. Khanani, Zdenka Hašková, Aaron Osborne, Susanna M. Grzeschik, Jayashree Sahni and Sunil Patel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Ophthalmology and The American Journal of Gastroenterology.

In The Last Decade

Karen Basu

9 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Basu United States 6 328 290 67 67 52 12 444
Viridiana Kocaba Singapore 14 362 1.1× 593 2.0× 141 2.1× 26 0.4× 37 0.7× 45 744
Akshay S. Thomas United States 12 369 1.1× 180 0.6× 43 0.6× 29 0.4× 39 0.8× 68 429
Marc Figueras‐Roca Spain 14 294 0.9× 201 0.7× 65 1.0× 10 0.1× 25 0.5× 44 400
Miltiadis Papathanassiou Greece 11 319 1.0× 310 1.1× 79 1.2× 24 0.4× 17 0.3× 32 534
Rohit Anand United States 7 127 0.4× 121 0.4× 73 1.1× 13 0.2× 69 1.3× 21 298
Ahmed A. Abdel-Kader Egypt 10 123 0.4× 100 0.3× 34 0.5× 15 0.2× 51 1.0× 25 296
W. Friedrichs Germany 8 262 0.8× 150 0.5× 42 0.6× 13 0.2× 61 1.2× 10 363
Hisashi Kataoka Japan 10 96 0.3× 106 0.4× 28 0.4× 33 0.5× 20 0.4× 34 448
Sharmila S. Boekhoorn Netherlands 9 583 1.8× 437 1.5× 127 1.9× 19 0.3× 62 1.2× 13 665
Päivi Ranta Finland 10 309 0.9× 237 0.8× 63 0.9× 8 0.1× 30 0.6× 12 445

Countries citing papers authored by Karen Basu

Since Specialization
Citations

This map shows the geographic impact of Karen Basu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Basu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Basu more than expected).

Fields of papers citing papers by Karen Basu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Basu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Basu. The network helps show where Karen Basu may publish in the future.

Co-authorship network of co-authors of Karen Basu

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Basu. A scholar is included among the top collaborators of Karen Basu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Basu. Karen Basu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Zou, Wen-Jun, Yanling Wang, Wenbin Wei, et al.. (2025). Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation. Asia-Pacific Journal of Ophthalmology. 14(1). 100142–100142.
2.
Hattenbach, Lars‐Olof, Francis Abreu, Karen Basu, et al.. (2023). BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion. SHILAP Revista de lepidopterología. 3(3). 100302–100302. 16 indexed citations
3.
Wells, John A., Charles C. Wykoff, Jeffrey R. Willis, et al.. (2021). Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials. Investigative Ophthalmology & Visual Science. 62(8). 1037–1037. 2 indexed citations
4.
Guymer, Robyn H., Carlos Quezada-Ruiz, Jeffrey R. Willis, et al.. (2021). Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design. Investigative Ophthalmology & Visual Science. 62(8). 429–429.
5.
Khanani, Arshad M., Jeffrey S. Heier, Carlos Quezada-Ruiz, et al.. (2021). Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials. Investigative Ophthalmology & Visual Science. 62(8). 428–428. 5 indexed citations
6.
Eter, Nicole, Rishi P. Singh, Francis Abreu, et al.. (2021). YOSEMITE and RHINE. SHILAP Revista de lepidopterología. 2(1). 100111–100111. 43 indexed citations
7.
Khanani, Arshad M., Robyn H. Guymer, Karen Basu, et al.. (2021). TENAYA and LUCERNE. SHILAP Revista de lepidopterología. 1(4). 100076–100076. 55 indexed citations
8.
Antoszyk, Andrew N., et al.. (2020). Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. Ophthalmology Retina. 4(10). 1034–1036.
9.
Khanani, Arshad M., Sunil Patel, Philip J. Ferrone, et al.. (2020). Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology. 138(9). 964–964. 133 indexed citations
10.
Danzig, Carl J., Carlos Quezada-Ruiz, Karen Basu, et al.. (2019). Efficacy and safety of faricimab every 16 or 12 weeks for neovascular age-related macular degeneration: STAIRWAY phase 2 results. 60(9). 1212–1212. 4 indexed citations
11.
Boyer, David S., Quan Dong Nguyen, David M. Brown, Karen Basu, & Jason S. Ehrlich. (2015). Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy. Ophthalmology. 122(12). 2504–2513.e1. 104 indexed citations
12.
Faubion, William A., Joel G. Fletcher, Sharon O’Byrne, et al.. (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal of Gastroenterology. 108(12). 1891–1900. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Viridiana Kocaba Breakdown of academic impact, for papers by Akshay S. Thomas Breakdown of academic impact, for papers by Marc Figueras‐Roca Breakdown of academic impact, for papers by Miltiadis Papathanassiou Breakdown of academic impact, for papers by Rohit Anand Breakdown of academic impact, for papers by Ahmed A. Abdel-Kader Breakdown of academic impact, for papers by W. Friedrichs Breakdown of academic impact, for papers by Hisashi Kataoka Breakdown of academic impact, for papers by Sharmila S. Boekhoorn Breakdown of academic impact, for papers by Päivi Ranta
Rankless by CCL
2026